Shares of Ampio Pharmaceuticals (AMPE -23.3%) sink after an article asserts Ampio's drug Zertane will not be approved by regulators. Ampio has been testing Zertane for the treatment of premature ejaculation, and the drug is currently in Phase III clinical trials. Quoting an (anonymous) biotech fund manager: "Zertane... is laughable and has zero chance of approval."
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs